Anika to Showcase HYALOFAST at the International Cartilage Regeneration and Joint Preservation Society (ICRS) Focus Meeting in Milan

From Startup Anika Therapeutics Link to Full Article: BEDFORD, Mass.–(BUSINESS WIRE)–Dec. 12, 2018– Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced plans to showcase its entire Orthobiologics franchise, including HYALOFAST, at

Aduro Biotech Data Published in Cell Reports Highlights the Significant Role of the Magnitude of Intratumoral STING Activation by ADU-S100 in Anti-Tumor Immunity

From Startup Aduro Biotech Link to Full Article: BERKELEY, Calif., Dec. 12, 2018 (GLOBE NEWSWIRE) — Aduro Biotech, Inc. (NASDAQ: ADRO) today announced the publication of a peer-reviewed paper in Cell Reports authored by Aduro scientists and Novartis collaborators as part of their ongoing research to study intratumoral stimulator of

Aptinyx to Present Preclinical Data on NMDA Receptor Modulator NYX-2925 at the American College of Neuropsychopharmacology’s Annual Meeting

From Startup Aptinyx Link to Full Article: EVANSTON, Ill., Dec. 11, 2018 (GLOBE NEWSWIRE) — Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced two upcoming poster presentations highlighting preclinical data on its novel NMDA receptor

Axovant Reports Results of Exploratory Phase 2 Clinical Study of Nelotanserin in Lewy Body Dementia Patients Experiencing REM Sleep Behavior Disorder

From Startup Axovant Link to Full Article: Primary efficacy endpoint assessed by sleep laboratory video assessment was not met Axovant is discontinuing clinical development of nelotanserin  BASEL, Switzerland, Dec. 10, 2018 (GLOBE NEWSWIRE) — Axovant Sciences (NASDAQ: AXON) a clinical-stage gene therapy company, today reported topline results of the

Stealth BioTherapeutics Granted Fast Track Designation for Elamipretide for the Treatment of Dry Age-Related Macular Degeneration with Geographic Atrophy

From Startup Stealth Biotherapeutics Link to Full Article: BOSTON – December 10, 2018 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its lead investigational candidate, elamipretide, for

Precision BioSciences and Durham STEM Students Lead Launch of First Genome Editing Experiment Into Space

From Startup Precision Biosciences Link to Full Article: CAPE CANAVERAL, FL, USA, December 6th, 2018 – Precision BioSciences today announced that the world’s first genome editing experiment in space has been launched aboard a SpaceX Dragon cargo spacecraft on a Falcon 9 rocket. The mission was launched from Cape

Neon Therapeutics and Apexigen Announce First Patient Dosed in Neon’s NT-003 Phase 1b Combination Trial of NEO-PV-01 in Metastatic Melanoma

From Startup Neon Therapeutics Link to Full Article: CAMBRIDGE, Mass. and SAN CARLOS, Calif., Dec. 06, 2018 (GLOBE NEWSWIRE) — Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, and Apexigen, Inc., a clinical-stage biopharmaceutical company, today announced that patient dosing has begun in NT-003, Neon’s Phase 1b

Dermavant Sciences to Present New Data on Cerdulatinib for Atopic Dermatitis and Vitiligo at the 3rd Annual Inflammatory Skin Disease Summit

From Startup Dermavant Link to Full Article: December 6, 2018 BASEL, Switzerland—Dec. 6, 2018—Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced that the company will present new data on cerdulatinib during the 3rd Annual Inflammatory Skin Disease Summit (ISDS) taking place Dec. 12-15, 2018, in Vienna, Austria.

Axovant Announces Feedback From FDA Meeting Regarding AXO-Lenti-PD for Parkinson’s Disease and Progress in Ongoing SUNRISE-PD Phase 2 Clinical Trial

From Startup Axovant Link to Full Article: Meeting with FDA confirmed that studies previously conducted using first generation ProSavin® may be considered part of a single development program with AXO-Lenti-PD Confirmed with FDA that the proposed current manufacturing process and quality control testing is adequate for the clinical program

Eidos Therapeutics Appoints William Lis to Board of Directors

From Startup Eidos Therapeutics Link to Full Article: SAN FRANCISCO, Dec. 06, 2018 (GLOBE NEWSWIRE) — Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large unmet need in transthyretin (TTR) amyloidosis (ATTR), today announced the appointment of William Lis, to Eidos’ Board of Directors,